Long-term exposure to MST-312 leads to telomerase reverse transcriptase overexpression in MCF-7 breast cancer cells

Anti-cancer Drugs
Karollyne S MoraisDiêgo M de Oliveira

Abstract

Telomerase is an enzyme responsible for telomere maintenance in almost all human cancer cells, but generally not expressed in somatic ones. Therefore, antitelomerase therapy is a potentially revolutionary therapeutic strategy, and the antitumor activity of telomerase inhibitors (TI) has been studied extensively recently, mainly for breast cancer. However, the effects expected from treatment with TI will appear only after many cell divisions, but the effects of this long-term approach are unknown. In this work, the consequences of 3120 h exposure of human breast cancer cells to TI MST-312 were investigated. MCF-7 cells were treated with MST-312 at a subtoxic concentration for a long time, and then cell morphology, viability, senescence, and proliferation were analyzed by phase-contrast microscopy, MTT assay, β-galactosidase test, and the trypan blue exclusion assay, respectively. Also, chromosomal stability was evaluated by classical cytogenetic analysis. The average length of telomeres and telomerase reverse transcriptase expression were accessed by real-time PCR and real-time RT-PCR, respectively. The MST-312 showed cytotoxic action and promoted telomere erosion, senescence, and chromosome aberrations, as expected, but in a sm...Continue Reading

References

Apr 10, 2009·Cancer Investigation·Karen S Anderson
Aug 28, 2012·Nucleic Acids Research·Loretta M S LauRoger R Reddel
Apr 6, 2013·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Hanna HolyszBlazej Rubis
Feb 18, 2014·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Aktan AlpsoyUfuk Gündüz
Jul 1, 2014·Current Pharmaceutical Design·Orit Uziel, Meir Lahav
Mar 12, 2015·Current Opinion in Oncology·Jeremy Lewin, Lillian L Siu
May 30, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ahmad FatemiAhmad Kazemi
May 30, 2015·Journal of Nutrigenetics and Nutrigenomics·Resham Lal GurungM Prakash Hande
Aug 8, 2015·Journal of Experimental & Clinical Cancer Research : CR·Tamara Fernández-MarceloPilar Iniesta
Sep 4, 2015·The New England Journal of Medicine·Gabriela M BaerlocherDavid S Snyder
Oct 31, 2015·Nature Reviews. Drug Discovery·Megan Cully
Apr 23, 2016·Expert Opinion on Therapeutic Patents·Ruo-Jun ManHai-Liang Zhu
May 31, 2016·Genes·Yucheng Xu, Amir Goldkorn
Jun 14, 2016·Neurochemistry International·Diêgo Madureira de OliveiraRamon Dos Santos El-Bachá

❮ Previous
Next ❯

Citations

Apr 24, 2019·Cell Biochemistry and Function·Karollyne da Silva MoraisDiêgo Madureira de Oliveira
Sep 21, 2019·Recent Patents on Anti-cancer Drug Discovery·Ying LiuFeng Shi
Jan 12, 2020·Current Topics in Medicinal Chemistry·Guilherme G da SilvaDiêgo M de Oliveira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Related Papers

Journal of Experimental & Clinical Cancer Research : CR
C Testorelli
Breast Cancer : the Journal of the Japanese Breast Cancer Society
Yaojian RaoJiawei Cui
Methods in Molecular Medicine
Kai-da Wu, Malcolm A S Moore
© 2022 Meta ULC. All rights reserved